Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02022215 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of ME1111 in Patients With Onychomycosis
A Phase 2 study of Onychomycosis, sponsored by Meiji Seika Pharma Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 304
- Enrollment target
- 20
- Study locations
NCT02022215 is a Phase 2 study of Onychomycosis that has completed, run by Meiji Seika Pharma Co.. The registered enrollment target is 304 participants, above the 67-participant average among 11 other Onychomycosis trials with a reported enrollment target (354% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT02022215, a Phase 2 study of Onychomycosis, has completed, sponsored by Meiji Seika Pharma Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 304 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to determine the safety and efficacy of high and low strength of ME1111 solutions compared to the vehicle in the treatment of onychomycosis of the toenail.
Conditions Studied
Interventions
- DRUG ME1111 Solution, Low strength
- DRUG ME1111 Solution, High strength
- DRUG Matching Vehicle Solution
Study Locations (20)
California
- - Encinitas
- - San Diego
- - San Francisco
- - Santa Rosa
Florida
- - Miami
- - Miramar
Michigan
- - Ann Arbor
- - Clinton Township
New York
- - New York
- - Rochester
Alabama
- - Birmingham
Colorado
- - Denver
Georgia
- - Newnan
Idaho
- - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 304 participants |
| Start Date | 2013-12-19 |
| Est. Completion | 2016-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02022215
The ClinicalTrials.gov registry entry for NCT02022215 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 304 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 67-participant average among 11 other Onychomycosis trials with a reported enrollment target (354% higher). The listed sponsor is Meiji Seika Pharma Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Onychomycosis appearing as the primary indexed condition, and to 3 interventions - of which ME1111 Solution, Low strength is the first listed.
NCT02022215 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT02022215 about?
NCT02022215 is a clinical study titled "Efficacy and Safety Study of ME1111 in Patients With Onychomycosis". The purpose of the study is to determine the safety and efficacy of high and low strength of ME1111 solutions compared to the vehicle in the treatment of onychomycosis of the toenail.
What is the current status of trial NCT02022215?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 304 participants. The study started on 2013-12-19. Estimated completion is 2016-03-01.
What conditions does trial NCT02022215 study?
This clinical trial studies the following conditions: Onychomycosis.
What interventions are being tested in trial NCT02022215?
The interventions under investigation include: ME1111 Solution, Low strength (DRUG), ME1111 Solution, High strength (DRUG), Matching Vehicle Solution (DRUG).
Who is sponsoring clinical trial NCT02022215?
This trial is sponsored by Meiji Seika Pharma Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02022215 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Onychomycosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II)
COMPLETED · Phase 2
-
Deposition of Terbinafine After Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail
COMPLETED · Phase 2
-
A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)
ACTIVE NOT RECRUITING · Phase 3
-
Treatment of Onychomycosis Using a 0.65 Millisecond Pulsed Nd:YAG 1064 nm Laser
COMPLETED · NA
-
Spread of Dermatophytes Among Families
COMPLETED
-
Study of the Use of Low Level Laser Light Therapy to Treat Toenail Fungus
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.